CINGAL Updated Aug 1
Watch Anika's Q3 2026 earnings call (next scheduled update) for a confirmation that the Cingal NDA was formally submitted and for FDA acceptance, that would finally give the stock a dated regulatory clock. Until a submission is confirmed, treat Cingal as a 2027+ US revenue story, not a near-term binary; near-term price action is being driven by the Q2 2026 earnings beat and guidance raise rather than by Cingal news.
- Clear regulatory route: the FDA has defined an NDA path requiring two studies including a bioequivalence study, with initiation on track for before year-end 2025 per the Nov 5, 2025 10-Q, a defined path rather than an open-ended clinical program.
- US launch would be a new revenue stream: Anika's commercial channel is already firing, record Commercial Channel revenue of $13.9M (+17% YoY) in Q2 2026, the same sales infrastructure a Cingal US approval would plug into.
- Wall Street is constructive on the stock: analyst consensus shows 7 of 8 ratings at Buy/Strong Buy (4 buy, 3 strong buy, 1 hold), mean price target of $21 (vs ~$19.28 current price), and B. Riley maintained Buy after the Q2 2026 beat.
- Timeline slippage: the NDA submission expected around Dec 31, 2025 (per the Nov 2025 10-Q) was still an open 'Cingal NDA timeline to monitor' as of the July 29, 2026 earnings report, no submission or FDA acceptance had been confirmed, and no PDUFA date exists in the data.
- No dated catalyst: with the next hard regulatory event unscheduled, there is no binary to trade; the stock moved only +0.63% (1-day) around the expected NDA-submission date, suggesting limited near-term price sensitivity to Cingal progress.
- FDA-timing precedent at the company: sibling product Hyalofast received an FDA deficiency letter and was removed from 2027 revenue guidance due to FDA timing uncertainty, evidence that this FDA pathway can slip.